{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"A complete response is defined as having resolution of WM related symptoms, normalization of serum IgM levels with complete disappearance of IgM paraprotein by immunofixation, and resolution of any adenopathy or splenomegaly.","groups":[{"description":"ABT199 will be administered daily, with 28 consecutive days defined as a treatment cycle for a maximum for 26 cycles\n\nABT199: Oral BCL-2 antagonist","id":"OG000","title":"ABT199"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"1 participant was censored from the response analysis after it was determined that he had IgM Myeloma rather than Waldenstrom's macroglobulinemia.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Number of Participants With Complete Response","type":"SECONDARY","unitOfMeasure":"Participants"}